

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

15 Jun 2026

### Effectiveness of Caffeine Augmentation in Partial-Response Obsessive Compulsive disorder Patients Treated with Selective serotonin reuptake inhibitors (SSRIs)

#### Protocol summary

##### Study aim

Efficacy of caffeine supplementation in patients with obsessive-compulsive disorder treated with Selective serotonin reuptake inhibitors (SSRIs) with partial response

##### Design

In this study, a phase 3, double blind randomized controlled clinical trial, 130 patients suffering from obsessive-compulsive disorder who were treated with serotonin reuptake inhibitor drugs with a random assignment software in two groups of 65 people distributed to the intervention group people who received caffeine tablets with a dose of 100 mg for one week and 200 mg in the second week and then 300 mg once a day. People in the control group will be given a placebo pill with the same form and protocol.

##### Settings and conduct

This double-blind study (where patients and researchers are unaware of the type of drug prescribed) will be conducted in 1405 and 1406 at Noor and Hazrat Ali Asghar Hospital in Isfahan. 130 patients with obsessive-compulsive disorder who are treated with serotonin reuptake inhibitors are divided into two groups receiving caffeine and placebo.

##### Participants/Inclusion and exclusion criteria

In this study, patients with obsessive-compulsive disorder who have been treated with serotonin reuptake inhibitor drugs for at least 12 weeks and who do not have psychotic thoughts addiction and do not have contraindications to opioid use are included in the study.

##### Intervention groups

In the intervention group, caffeine tablets with a dose of 100 mg will be given for one week, then 200 mg in the second week, and then 300 mg once a day, and placebo tablets with the same shape and protocol will be added to the control group.

##### Main outcome variables

Obsessive compulsive score

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20090801002266N23**

Registration date: **2026-05-31, 1405/03/10**

Registration timing: **registered\_while\_recruiting**

Last update: **2026-06-14, 1405/03/24**

Update count: **2**

##### Registration date

2026-05-31, 1405/03/10

##### Registrant information

##### Name

Gholamreza Kheirabadi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 1222 2135

##### Email address

kheirabadi@bsrc.mui.ac.ir

##### Recruitment status

**recruiting**

##### Funding source

##### Expected recruitment start date

2026-05-22, 1405/03/01

##### Expected recruitment end date

2027-03-20, 1405/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

## Trial completion date

empty

## Scientific title

Effectiveness of Caffeine Augmentation in Partial-Response Obsessive Compulsive disorder Patients Treated with Selective serotonin reuptake inhibitors (SSRIs)

## Public title

Evaluation of adding Caffeine to SSRI in patients with Obsessive-Compulsive Disorders

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

CD diagnosis based on clinical interview based on DSM5 clinical criteria Outpatients with at least 12 weeks (3 months) of SSRI treatment and partial response. Ability to read and write Patient consent to participate in the study

### Exclusion criteria:

Pregnancy Drug abuse (based on patient report or file contents) Existence of suicidal thoughts (based on the report or content of the patient's file) The presence of psychotic symptoms based on the patient's report Diseases that can prevent the use of caffeine Taking other medications along with an SSRI, including antipsychotics, anticonvulsants, stimulants, or other augmenting medications, or taking more than one type of SSRI Excessive caffeine consumption

## Age

From **18 years** old to **55 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Participant
- Investigator

## Sample size

Target sample size: **130**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization of patients between two groups is done with random assignment software. In this software, the total volume of the sample and the number of groups are entered into the software. The output of the software is a list that shows the total number of samples numerically and randomly distributed in two groups. Patients are distributed in two groups according to the time of visit and according to the mentioned list, so that the sample size reaches the required number.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

The study was double-blind, and the researcher and the patients were unaware of the type of drug received. Allocation of drug packages to patients will be done by the pharmacist using random coding. The researchers

will only receive the random code and will not know the drug or placebo content until the end of the data analysis.

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Isfahan University of Medical Sciences

##### Street address

Research faculty, Isfahan University of Medical Sciences, Hezar Jerib street, Isfahan, Iran

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8434193474

#### Approval date

2026-02-20, 1404/12/01

#### Ethics committee reference number

IR.MUI.MRD.REC.1404.466

## Health conditions studied

### 1

#### Description of health condition studied

Obsessive Compulsive Disorder

#### ICD-10 code

F42.0

#### ICD-10 code description

Obsessive-compulsive disorder

## Primary outcomes

### 1

#### Description

Obsessive Compulsive disorder scale

#### Timepoint

At start and end of intervention

#### Method of measurement

With Y-BOCS questionnaire

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Received Caffeine 100 mg for one week, then 200 mg caffeine for tnd week and then 300 mg caffeine for third week.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Received plaseboo for three weeks same to intervention group.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Noor & Ali Asghar hospital

##### Full name of responsible person

Gholamreza KHeirabadi

##### Street address

Noor & Ali Asghar hospital, Ostandari street, isfahan, Iran

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8434193474

##### Phone

+98 31 3669 2174

##### Email

kheirabadi@bsrc.mui.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Esfahan University of Medical Sciences

##### Full name of responsible person

Gholamreza Askari

##### Street address

Research faculty, Isfahan University of Medical Sciences, Hezar Jerib street, Isfahan, Iran

##### City

Isfahan

##### Province

Isfahan

##### Postal code

843419347

##### Phone

+98 31 3792 3060

#### Email

askari@ui.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Esfahan University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Esfahan University of Medical Sciences

##### Full name of responsible person

Gholamreza Kheirabadi

##### Position

Associate professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Psychiatrics

##### Street address

Clinical psychology department, Noor & Ali Asghar hospital, Ostandari street, Isfahan, Iran

##### City

Isfahan

##### Province

Isfahan

##### Postal code

8434193474

##### Phone

+98 31 3669 2174

##### Email

kheirabadi@bsrc.mui.ac.ir

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Esfahan University of Medical Sciences

##### Full name of responsible person

Gholamreza Kheirabadi

##### Position

Associate professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Psychiatrics

**Street address**

Department of clinical psychology, Noor & Ali Asghar hospital, Ostandari street, Isfahan, Iran

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8434193474

**Phone**

+98 31 3669 2174

**Email**

kheirabadi@bsrc.mui.ac.ir

of Medical Sciences, Hezar Jerib street, Isfahan, Iran

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8434193474

**Phone**

+98 31 3792 9520

**Email**

al.mehrabi@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Esfahan University of Medical Sciences

**Full name of responsible person**

Ali Mehrabi

**Position**

Statistical Consultant

**Latest degree**

Master

**Other areas of specialty/work**

Epidemiology

**Street address**

Research faculty, medical school, Isfahan University

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

The plan belonging to government and we cant sharing it.

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available